JP7110491B2 - ヒト補体因子ｃ２ｂに対する抗体及び使用方法 - Google Patents

ヒト補体因子ｃ２ｂに対する抗体及び使用方法 Download PDF

Info

Publication number
JP7110491B2
JP7110491B2 JP2021533300A JP2021533300A JP7110491B2 JP 7110491 B2 JP7110491 B2 JP 7110491B2 JP 2021533300 A JP2021533300 A JP 2021533300A JP 2021533300 A JP2021533300 A JP 2021533300A JP 7110491 B2 JP7110491 B2 JP 7110491B2
Authority
JP
Japan
Prior art keywords
monoclonal antibody
seq
amino acid
domain
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021533300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512223A (ja
Inventor
ブランシェット クリストフ
デ ハード ハンス
Original Assignee
アルジェニクス ビーブイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルジェニクス ビーブイ filed Critical アルジェニクス ビーブイ
Publication of JP2022512223A publication Critical patent/JP2022512223A/ja
Priority to JP2022115252A priority Critical patent/JP7611191B2/ja
Application granted granted Critical
Publication of JP7110491B2 publication Critical patent/JP7110491B2/ja
Priority to JP2024125608A priority patent/JP2024160274A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Devices For Post-Treatments, Processing, Supply, Discharge, And Other Processes (AREA)
JP2021533300A 2018-12-13 2019-12-13 ヒト補体因子ｃ２ｂに対する抗体及び使用方法 Active JP7110491B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022115252A JP7611191B2 (ja) 2018-12-13 2022-07-20 ヒト補体因子ｃ２ｂに対する抗体及び使用方法
JP2024125608A JP2024160274A (ja) 2018-12-13 2024-08-01 ヒト補体因子ｃ２ｂに対する抗体及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779102P 2018-12-13 2018-12-13
US62/779,102 2018-12-13
PCT/IB2019/060802 WO2020121282A1 (en) 2018-12-13 2019-12-13 Antibodies to human complement factor c2b and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022115252A Division JP7611191B2 (ja) 2018-12-13 2022-07-20 ヒト補体因子ｃ２ｂに対する抗体及び使用方法

Publications (2)

Publication Number Publication Date
JP2022512223A JP2022512223A (ja) 2022-02-02
JP7110491B2 true JP7110491B2 (ja) 2022-08-01

Family

ID=69143627

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021533300A Active JP7110491B2 (ja) 2018-12-13 2019-12-13 ヒト補体因子ｃ２ｂに対する抗体及び使用方法
JP2022115252A Active JP7611191B2 (ja) 2018-12-13 2022-07-20 ヒト補体因子ｃ２ｂに対する抗体及び使用方法
JP2024125608A Pending JP2024160274A (ja) 2018-12-13 2024-08-01 ヒト補体因子ｃ２ｂに対する抗体及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022115252A Active JP7611191B2 (ja) 2018-12-13 2022-07-20 ヒト補体因子ｃ２ｂに対する抗体及び使用方法
JP2024125608A Pending JP2024160274A (ja) 2018-12-13 2024-08-01 ヒト補体因子ｃ２ｂに対する抗体及び使用方法

Country Status (21)

Country Link
US (4) US11161900B2 (enExample)
EP (2) EP4375297A3 (enExample)
JP (3) JP7110491B2 (enExample)
KR (2) KR102774146B1 (enExample)
CN (2) CN113260375B (enExample)
AU (3) AU2019397614B2 (enExample)
BR (1) BR112021011107A2 (enExample)
CA (1) CA3119655A1 (enExample)
DK (1) DK3893924T3 (enExample)
EA (1) EA202191658A1 (enExample)
ES (1) ES2991894T3 (enExample)
FI (1) FI3893924T3 (enExample)
HU (1) HUE068993T2 (enExample)
IL (2) IL319975A (enExample)
LT (1) LT3893924T (enExample)
MX (2) MX2021006864A (enExample)
PL (1) PL3893924T3 (enExample)
PT (1) PT3893924T (enExample)
SG (1) SG11202105195PA (enExample)
WO (1) WO2020121282A1 (enExample)
ZA (1) ZA202407097B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022160479A (ja) * 2018-12-13 2022-10-19 アルジェニクス ビーブイ ヒト補体因子ｃ２ｂに対する抗体及び使用方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
GB202407051D0 (en) 2024-05-17 2024-07-03 argenx BV Methods of treating osteoarthritis pain
WO2025257157A1 (en) 2024-06-10 2025-12-18 argenx BV Treatment or prevention of ischemia reperfusion injury in organ tranplantation
WO2025260123A1 (en) * 2024-06-17 2025-12-26 CSL Innovation Pty Ltd Anti-c2 antibodies and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520313A (ja) 2013-05-23 2016-07-14 ブロテイオ ファーマ ビーヴィＢｒｏｔｅｉｏ Ｐｈａｒｍａ Ｂ．Ｖ． ヒト補体因子ｃ２に結合する結合分子、及び、その使用。
WO2017087800A1 (en) 2015-11-19 2017-05-26 Abbvie Stemcentrx Llc Novel anti-emr2 antibodies and methods of use
WO2017132259A1 (en) 2016-01-25 2017-08-03 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch
WO2018107109A1 (en) 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Novel anti-kremen2 antibodies and methods of use
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998468B2 (en) * 2000-03-23 2006-02-14 Tanox, Inc. Anti-C2/C2a inhibitors of complement activation
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
BRPI0908312A2 (pt) 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010056399A1 (en) 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
BR112012033119A2 (pt) * 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
US9206257B2 (en) * 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
PL2753636T3 (pl) 2011-09-07 2020-05-18 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
WO2014096958A1 (en) 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
ES2912396T3 (es) * 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
EP2997045A4 (en) 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
CA2859114A1 (en) 2013-08-29 2015-02-28 International Automotive Components Group North America, Inc. Formed articles comprising carbon and natural fibers, methods of manufacture and use thereof
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
RS61351B1 (sr) * 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
WO2015089368A2 (en) 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
PL3215527T3 (pl) 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
FI3380518T3 (fi) 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
RU2018130525A (ru) 2016-01-27 2020-02-27 Цсл Беринг Ленгнау Аг РЕКОМБИНАНТНЫЕ Fc-МУЛЬТИМЕРЫ IgG
WO2017196960A1 (en) 2016-05-10 2017-11-16 Annexon, Inc. Anti-complement factor c4/c4b antibodies and uses thereof
SG11201907583TA (en) 2017-03-14 2019-09-27 Bioverativ Usa Inc Methods for treating complement-mediated diseases and disorders
CA3078971A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
PL3893924T3 (pl) 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520313A (ja) 2013-05-23 2016-07-14 ブロテイオ ファーマ ビーヴィＢｒｏｔｅｉｏ Ｐｈａｒｍａ Ｂ．Ｖ． ヒト補体因子ｃ２に結合する結合分子、及び、その使用。
WO2017087800A1 (en) 2015-11-19 2017-05-26 Abbvie Stemcentrx Llc Novel anti-emr2 antibodies and methods of use
WO2017132259A1 (en) 2016-01-25 2017-08-03 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch
WO2018107109A1 (en) 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Novel anti-kremen2 antibodies and methods of use
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022160479A (ja) * 2018-12-13 2022-10-19 アルジェニクス ビーブイ ヒト補体因子ｃ２ｂに対する抗体及び使用方法
JP7611191B2 (ja) 2018-12-13 2025-01-09 アルジェニクス ビーブイ ヒト補体因子ｃ２ｂに対する抗体及び使用方法

Also Published As

Publication number Publication date
HUE068993T2 (hu) 2025-02-28
IL319975A (en) 2025-05-01
JP7611191B2 (ja) 2025-01-09
KR102774146B1 (ko) 2025-02-26
JP2022160479A (ja) 2022-10-19
PT3893924T (pt) 2024-10-09
IL283916B1 (en) 2025-05-01
US11708403B2 (en) 2023-07-25
JP2024160274A (ja) 2024-11-13
US20220119509A1 (en) 2022-04-21
AU2022287637B2 (en) 2025-07-17
IL283916B2 (en) 2025-09-01
IL283916A (en) 2021-07-29
AU2019397614A1 (en) 2021-06-03
ZA202407097B (en) 2026-04-29
MX2021006864A (es) 2021-07-02
AU2025252632A1 (en) 2025-11-06
ES2991894T3 (es) 2024-12-05
SG11202105195PA (en) 2021-06-29
US11591386B2 (en) 2023-02-28
MX2025010337A (es) 2025-10-01
DK3893924T3 (da) 2024-11-04
PL3893924T3 (pl) 2025-01-13
BR112021011107A2 (pt) 2021-12-14
US20220267424A1 (en) 2022-08-25
NZ776117A (en) 2024-07-26
EA202191658A1 (ru) 2021-11-03
AU2022287637A1 (en) 2023-02-02
EP4375297A3 (en) 2024-10-30
US11161900B2 (en) 2021-11-02
EP3893924B1 (en) 2024-08-21
EP3893924A1 (en) 2021-10-20
CN119371526A (zh) 2025-01-28
EP4375297A2 (en) 2024-05-29
KR20210100688A (ko) 2021-08-17
WO2020121282A1 (en) 2020-06-18
KR20250030005A (ko) 2025-03-05
LT3893924T (lt) 2024-10-10
JP2022512223A (ja) 2022-02-02
CN113260375B (zh) 2024-10-01
FI3893924T3 (fi) 2024-10-04
US20240002484A1 (en) 2024-01-04
CN113260375A (zh) 2021-08-13
US20200239554A1 (en) 2020-07-30
CA3119655A1 (en) 2020-06-18
AU2019397614B2 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
US11053306B2 (en) Fusion protein constructs comprising anti-C3d antibody and factor H
JP7611191B2 (ja) ヒト補体因子ｃ２ｂに対する抗体及び使用方法
HK40121588A (en) Antibodies to human complement factor c2b and methods of use
HK40104765A (en) Antibodies to human complement factor c2b and methods of use
HK40051472A (en) Antibodies to human complement factor c2b and methods of use
HK40051472B (en) Antibodies to human complement factor c2b and methods of use
EA052525B1 (ru) Антитела против фактора c2b комплемента человека и способы применения
HK40050349B (en) Antibodies to human complement factor c2b and methods of use
EA046598B1 (ru) Антитела против фактора c2b комплемента человека и способы применения
HK40050349A (en) Antibodies to human complement factor c2b and methods of use
CA3123004C (en) Fusion protein constructs for complement associated disease
WO2025260123A1 (en) Anti-c2 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210806

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220621

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220720

R150 Certificate of patent or registration of utility model

Ref document number: 7110491

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250